

Oregon Health & Science University Hospital and Clinics Provider's Orders



ADULT AMBULATORY INFUSION ORDER Risankizumab-rzaa (SKYRIZI)

Page 1 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Weight:kg	Height:cm
Allergies:	
Diagnosis Code:	
Treatment Start Date:	Patient to follow up with provider on date:

GUIDELINES FOR ORDERING

- 1. Send FACE SHEET and H&P or most recent chart note.
- 2. A Tuberculin test must have been placed and read as negative prior to initiation of treatment (PPD or QuantiFERON Gold blood test). If result is indeterminate, a follow up chest X-ray must be performed to rule out TB. Please send results with order.
- 3. Risankizumab-rzza may increase the risk of infection. Instruct patient to inform healthcare provider if they develop any symptoms of an infection. Treatment should not be initiated or continued in patients with any clinically important active infection until the infection is resolved or treated.
- 4. Patient should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently.
- 5. Monitor liver enzymes and bilirubin levels at baseline and during induction, up to at least 12 weeks of treatment.

PRE-SCREENING: (Results must be available prior to initiation of therapy):

- ☐ Tuberculin skin test or QuantiFERON Gold blood test results scanned with orders.
- ☐ Chest X-Ray result scanned with orders if TB test result is indeterminate.

LABS:

• CMP, Routine, ONCE, every visit

NURSING ORDERS:

- 1. TREATMENT PARAMETER Hold treatment and contact provider if TB test result is positive or if screening has not been performed.
- 2. Monitor for signs and symptoms of infection. Advise patient to report symptoms of infection.
- 3. For signs and symptoms of active infection contact provider prior to administering.
- 4. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

^{**}This plan will expire after 365 days at which time a new order will need to be placed**



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER Risankizumab-rzaa (SKYRIZI)

Page 2 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

MEDICATIONS:	
☐ Crohn's Disease – 600 mg in dex	very 4 weeks x 3 doses (Week 0, Week 4, & Week 8) ktrose 5%, intravenous, over 1 hour extrose 5%, intravenous, over 2 hours
& Medicaid Services Self-Administration	aneous injections are included on the Center for Medicare Drug Exclusion List. An outpatient prescription for leed to be supplied by the provider for patients with re B) for self-administration.
☐ risankizumab-rzaa (SKYRIZI), 360 m thereafter.	g, subcutaneous, ONCE at week 12 and every 8 weeks
 infusion and notify provider immediately. Adr Algorithm for Acute Infusion Reaction (OHSU symptom monitoring and continuously asses 2. diphenhydrAMINE (BENADRYL) injection, 20 hypersensitivity or infusion reaction 3. EPINEPHrine HCI (ADRENALIN) injection, 00 hypersensitivity or infusion reaction 4. hydrocortisone sodium succinate (SOLU-CO dose for hypersensitivity or infusion reaction 	5-50 mg, intravenous, AS NEEDED x 1 dose for 0.3 mg, intramuscular, AS NEEDED x 1 dose for 0RTEF) injection, 100 mg, intravenous, AS NEEDED x 1
By signing below, I represent the following: I am responsible for the care of the patient (who is in I hold an active, unrestricted license to practice mediate that corresponds with state where you provide care state if not Oregon);	
My physician license Number is # PRESCRIPTION); and I am acting within my scope medication described above for the patient identified	(MUST BE COMPLETED TO BE A VALID of practice and authorized by law to order Infusion of the d on this form.
Provider signature:	Date/Time:

Printed Name:_____ Phone: _____ Fax:_____



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER Risankizumab-rzaa (SKYRIZI)

Page 3 of 3

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Central Intake:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

□ Beaverton

OHSU Knight Cancer Institute 15700 SW Greystone Court Beaverton, OR 97006

Phone number: 971-262-9000 Fax number: 503-346-8058

☐ Gresham

Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030

Phone number: 971-262-9500 Fax number: 503-346-8058

□ NW Portland

Legacy Good Samaritan campus Medical Office Building 3, Suite 150 1130 NW 22nd Ave.

Phone number: 971-262

Phone number: 971-262-9600 Fax number: 503-346-8058

□ Tualatin

Legacy Meridian Park campus Medical Office Building 2, Suite 140 19260 SW 65th Ave. Tualatin, OR 97062

Phone number: 971-262-9700 Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders